Practice Areas - Corporate and M&A Law Firms and Lawyers
| Deal Date: | 21-08-2015 | Practice Area: | Corporate and M&A |
| Deal Title: | GlaxoSmithKline Divestment of Rights in Ofatumumab | Industry: | Pharmaceuticals & Biotechnology |
| Description: |
Slaughter and May advised GlaxoSmithKline plc on the divestment to Novartis of its rights in ofatumumab for auto-immune indications, including multiple sclerosis, for up to USD1 billion. Novartis intended to pay USD300 million on closing, with further payments of up to USD734 million on the achievement of certain milestones and royalties of up to 12% on future sales.
Intellectual Property and Commercial: Susie Middlemiss (partner), Laura Houston (associate), Emma Lloyd-Jones (associate), Max Schofield (trainee).
|
||
| Financial Center: | London | Value: | 0.00-0.00 |
| Advised Party: | Service Provider | Law Firm | Slaughter and May |
| Contract Counterparty | United Kingdom | Contract Counterparty | United Kingdom |
| Classification: |
Commercial Contracts and Outsourcing IP Rights and Branding Agreements |
Lawyer | Susie Middlemiss |
